Rationale for therapy with low dose steroids combined with long-acting beta2-agonists in patients with allergic asthma: redirecting innate immune responses by long-term treatment with high doses of inhaled steroids

GlaxoSmithKline0 个研究点开始时间: 2007年8月30日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Inclusion criteria for entry into the run-in period:
•1. Male or female subjects =18 years = 50 years
•2. Allergic asthma: positive skin prick test for at least one aeroallergen or RAST
•3. Documented history of asthma according to GINA guidelines for a period of at least 6 months
•3. Subjects who have received regular treatment with FP at a dose of 250 mcg bd or equivalent with or without a LABA for at least 4 weeks before start of the run-in period, at a constant dose
•4. Subjects with history of recurrent episodes of wheezing, breathlessness, chest tigthness and/or coughing in the previous year
•5. Subjects who are able to use a DISKUS inhaler
•6. Subjects who are able to perform reproducible lung function tests at Visit 1 (variation FEV1 smaller than 5% between the two best measurements)
•Inclusion criteria for entry into the treatment period:
•1. Subjects with an FEV1% of predicted bigger than 70%
•2. ACT score smaller then 25 after the run-in period
•3. Negative pregnancy urine test when of child bearing potential
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Exclusion criteria for entry into the run-in period:
•1. Subjects who have been hospitalised for their asthma within 4 weeks of visit 1
•2. Subjects who had an acute upper respiratory tract infection within 4 weeks or a lower respiratory tract infection within 4 weeks prior to visit 1
•3. Subjects who received oral, parental, or depot corticosteroids within 4 weeks prior to visit 1
•4. Subjects who have a known respiratory disorder other than asthma and/or systemic/thoracic abnormalities which influence normal lung function
•5. Subjects who hae received any investigational drugs within 4 weeks of visit 1
•6. Subjects with a known or suspected hypersensitivity to inhaled steroids, beta2-agonists or lactose
•7. Subjects who use any medication that significantly inhibits the cytochrome P450 subfamily enzyme CYP3A4, including ritonavir, ketoconazole, itraconazole and erythromycin
•8. Subjects who concurrently participate in another clinical study
•9. Subjects who have previously been randomised in this study
•10. Subjects who have currently smoke or subjects who smoked in the last 6 months prior to the study
•11. Subjects with hepatic impairment or other significant disease.
•Exclusion criteria for entry into the treatment period:
•1. Any change in their run-in asthma medication
•2. Non-compliance with the run-in medication (smaller than 70%)

发起方